CONGRESS PRESENTATIONS

EACS 2023

October 18-21, 2023
Warsaw, Poland

2023 Post Fall Conference

Scientific Engagement Webinar - with panel discussion

ON DEMAND

Dolutegravir-based Regimens

Noe S, et al.

3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-Treated People Living with HIV-1 (PLHIV) in Germany: Real-world Data From the German URBAN Cohort

Download

View
×

Noe S, et al.

3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-Treated People Living with HIV-1 (PLHIV) in Germany: Real-world Data From the German URBAN Cohort
Collapse ❯ Expand ❮
Download

Letang E, et al.

Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People with HIV-1 (PWH) Aged > 50 Years

Download

View
×

Letang E, et al.

Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People with HIV-1 (PWH) Aged > 50 Years
Collapse ❯ Expand ❮
Download

Letang E, et al.

Real-world effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naïve People with HIV-1 (PWH) and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review

Download

View
×

Letang E, et al.

Real-world effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naïve People with HIV-1 (PWH) and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review
Collapse ❯ Expand ❮
Download

Patel P, et al.

No significant difference in incident hypertension observed by gender, race, baseline BMI or other key subgroups through week 96 among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials

Download

View
×

Patel P, et al.

No significant difference in incident hypertension observed by gender, race, baseline BMI or other key subgroups through week 96 among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials
Collapse ❯ Expand ❮
Download

Philibert P, et al.

CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine Fixed Dose Combination (FDC) in treatment-naïve adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results.

Download

View
×

Philibert P, et al.

CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine Fixed Dose Combination (FDC) in treatment-naïve adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results.
Collapse ❯ Expand ❮
Download

Cabotegravir Treatment

De los Santos Gil I, et al.

SOLAR 12-month European results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF

Download

View
×

De los Santos Gil I, et al.

SOLAR 12-month European results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF
Collapse ❯ Expand ❮
Download

Jonsson-Oldenbuettel C, et al.

Efficacy, safety, and implementation outcomes of cabotegravir + rilpivirine long-acting by country in the cabotegravir and rilpivirine implementation study in European locations (CARISEL)

Download

View
×

Jonsson-Oldenbuettel C, et al.

Efficacy, safety, and implementation outcomes of cabotegravir + rilpivirine long-acting by country in the cabotegravir and rilpivirine implementation study in European locations (CARISEL)
Collapse ❯ Expand ❮
Download

Ghosn J, et al.

Cabotegravir + rilpivirine long-acting efficacy and safety outcomes by sex at birth, age, and race: a subgroup analysis of the CARISEL study

Download

View
×

Ghosn J, et al.

Cabotegravir + rilpivirine long-acting efficacy and safety outcomes by sex at birth, age, and race: a subgroup analysis of the CARISEL study
Collapse ❯ Expand ❮
Download

Cabotegravir Prevention

Schroeder M, et al.

Drivers of discontinuation of oral PrEP within Europe: Findings from a real-world survey of PrEP use

Download

View
×

Schroeder M, et al.

Drivers of discontinuation of oral PrEP within Europe: Findings from a real-world survey of PrEP use
Collapse ❯ Expand ❮
Download

Fostemsavir

Wonderlich ER, et al.

Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial

Download

View
×

Wonderlich ER, et al.

Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial
Title
Presenter Disclosure Information
Introduction
Study Design and Efficacy Analysis
Mean Change From Baseline in sCD14 Over Time
Mean Change From Baseline in Other Inflammation-Related Biomarkers Over Time
Conclusions
Acknowledgments
Disclaimer
Collapse ❯ Expand ❮
Download

Llibre JM, et al.

Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHTE Study

Download

View
×

Llibre JM, et al.

Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHTE Study
Collapse ❯ Expand ❮
Download

Castagna A, et al.

Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240

Download

View
×

Castagna A, et al.

Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240
Collapse ❯ Expand ❮
Download

Pipeline

Leone P, et al.

Safety and Tolerability of VH3810109 (N6LS) Among Antiretroviral Therapy–Naive Adults Living With HIV-1: Results From the Monotherapy Phase of the Phase IIa BANNER Study

Download

View
×

Leone P, et al.

Safety and Tolerability of VH3810109 (N6LS) Among Antiretroviral Therapy–Naive Adults Living With HIV-1: Results From the Monotherapy Phase of the Phase IIa BANNER Study
Title
Presenter Disclosure Information
Introduction
BANNER Study Design
N6LS Led to Virologic Response in 13/14 Participants
BANNER Demographics and Baseline Characteristics
Safety Summary: Monotherapy Phase
Summary of Drug-Related Adverse Events: Monotherapy Phase
Summary of Infusion/Injection Site Reactions: Monotherapy Phase
Conclusions
Acknowledgments
Disclaimer
Collapse ❯ Expand ❮
Download

Joshi SR, et al.

Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 (GSK’254) as Part of a 2-Drug Regimen (2DR) in Treatment-Naive Adults: 24-Week Results from the Phase IIb DYNAMIC Study

Download

View
×

Joshi SR, et al.

Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 (GSK’254) as Part of a 2-Drug Regimen (2DR) in Treatment-Naive Adults: 24-Week Results from the Phase IIb DYNAMIC Study
Title
Speaker Disclosures
Introduction
Study Design and Endpoints
Baseline Characteristics
Results: Week 24 Efficacy
Results: Week 24 Efficacy (cont)
Results: Week 24 Safety
Conclusions
Acknowledgments
Disclaimer
Collapse ❯ Expand ❮
Download

Joshi SR, et al.

Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Randomized, Dose-Range Finding DOMINO Study

Download

View
×

Joshi SR, et al.

Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Randomized, Dose-Range Finding DOMINO Study
Title
Presenter Disclosure Information
Introduction
Study Design and Endpoints
Baseline Characteristics
Results: Week 24 Efficacy
Results: Week 24 Efficacy (cont)
Protocol-Defined Virologic Failure
Results: Week 24 Safety
Conclusions
Acknowledgments
Disclaimer
Collapse ❯ Expand ❮
Download

Edwards AY, et al.

Utilizing Population Modeling Approaches to Evaluate the Pharmacokinetics and Virological Activity of VH3810109 (N6LS) in the Phase IIa BANNER Study

Download

View
×

Edwards AY, et al.

Utilizing Population Modeling Approaches to Evaluate the Pharmacokinetics and Virological Activity of VH3810109 (N6LS) in the Phase IIa BANNER Study
Collapse ❯ Expand ❮
Download

Above Brand

O'Brien P, et al.

Drivers of satisfaction and quality of life of people living with HIV within Europe: Findings from a real-world survey of people living with HIV

Download

View
×

O'Brien P, et al.

Drivers of satisfaction and quality of life of people living with HIV within Europe: Findings from a real-world survey of people living with HIV
Title
Presenter Disclosure Information
Introduction
Overview of the Disease Specific Programme (DSP)™
Demographics and Baseline Characteristics
There Were Some Differences in Perceptions of Treatment Satisfaction Between Physicians and People Living With HIV
Physicians and People Living With HIV Highlighted Impact on HRQoL as Their Reason for Not Being Very Satisfied With Their Current ART
Health Status Was Assessed Using the EQ-5D-5L, and HRQoL Was Assessed Using the HIV-Specific PozQoL Instrument
HIV-Specific Instruments Are Needed to Fully Capture the Burden of HIV
People Living With HIV Still Reported Mental Health Burdens Related to Their ART
Physicians Highlighted the Important Role of Long-Acting Injectables to Address Key Issues With HIV Treatment
Conclusions
Acknowledgments
Disclaimer
Collapse ❯ Expand ❮
Download

Moskwa M, et al.

Patients' fears and expectations related to HIV infection and its treatment in Poland. A Positive Perspective 2 substudy

Download

View
×

Moskwa M, et al.

Patients' fears and expectations related to HIV infection and its treatment in Poland. A Positive Perspective 2 substudy
Collapse ❯ Expand ❮
Download

This content was acquired following an unsolicited medical information enquiry by a healthcare professional.  Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license.  In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes

No

Connect With Our Medical Experts

Find My ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1‑888‑226‑8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Our Response to COVID-19

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch